Effects of pentoxifylline on inflammatory parameters in chronic kidney disease patients: A randomized trial

Journal of Nephrology

Volumn 25, Issue 6, 2012, Pages 969-975

  Goicoechea, Marian ^a   de Vinuesa, Soledad García ^a   Quiroga, Borja ^a   Verdalles, Ursula ^a   Barraca, Daniel ^a   Yuste, Claudia ^a   Panizo, Nayara ^a   Verde, Eduardo ^a   Angeles Munoz M ^a   Luño, José ^a  

^a HOSPITAL GENERAL UNIVERSITARIO GREGORIO MARAÑÓN   (Spain)

Author keywords

Chronic kidney disease; Inflammation; Pentoxifylline

Indexed keywords

ALBUMIN; C REACTIVE PROTEIN; FIBRINOGEN; PENTOXIFYLLINE; TUMOR NECROSIS FACTOR ALPHA;

ARTICLE; BLEEDING; BLOOD PRESSURE REGULATION; CHRONIC KIDNEY DISEASE; CONTROLLED STUDY; DIASTOLIC BLOOD PRESSURE; DISEASE COURSE; DRUG EFFECT; DRUG SAFETY; DRUG WITHDRAWAL; FIBRINOGEN BLOOD LEVEL; GASTROINTESTINAL SYMPTOM; GLOMERULUS FILTRATION RATE; HUMAN; INFLAMMATION; KIDNEY FUNCTION; MAJOR CLINICAL STUDY; OUTCOME ASSESSMENT; PROSPECTIVE STUDY; RANDOMIZED CONTROLLED TRIAL; SYSTOLIC BLOOD PRESSURE; URINARY EXCRETION;

ALBUMINURIA; ANTI-INFLAMMATORY AGENTS; BIOLOGICAL MARKERS; C-REACTIVE PROTEIN; CHI-SQUARE DISTRIBUTION; DISEASE PROGRESSION; FIBRINOGEN; GLOMERULAR FILTRATION RATE; HUMANS; INFLAMMATION MEDIATORS; PENTOXIFYLLINE; PROSPECTIVE STUDIES; RENAL INSUFFICIENCY, CHRONIC; SPAIN; TIME FACTORS; TREATMENT OUTCOME; TUMOR NECROSIS FACTOR-ALPHA;

EID: 84870581145     PISSN: 11218428     EISSN: 17246059     Source Type: Journal    
DOI: 10.5301/jn.5000077     Document Type: Article

References (20)

1. Ehrly AM. Improvement of the flow properties of blood: a new therapeutical approach in occlusive arterial disease. Angiology. 1976;27(3):188-196.
2. Ward A, Clissold SP. Pentoxifylline. A review of its pharmacodynamic and pharmacokinetic properties, and its therapeutic efficacy. Drugs. 1987;34(1):50-97.
3. Sinzinger H. Pentoxifylline enhances formation of prostacyclin from rat vascular and renal tissue. Prostaglandins Leukot Med. 1983;12(2):217-226.
4. Gallardo JM, de Carmen Prado-Uribe M, Amato D, Paniagua R. Inflammation and oxidative stress markers by pentoxifylline treatment in rats with chronic renal failure and high sodium intake. Arch Med Res. 2007;38(1):34-38.
5. Navarro JF, Mora C, Rivero A, et al. Urinary protein excretion and serum tumor necrosis factor in diabetic patients with advanced renal failure: effects of pentoxifylline administration. Am J Kidney Dis. 1999;33(3):458-463.
6. Navarro JF, Mora C, Muros M, García J. Additive antiproteinuric effect of pentoxifylline in patients with type 2 diabetes under angiotensin II receptor blockade: a short-term, randomized, controlled trial. J Am Soc Nephrol. 2005;16(7):2119-2126.
7. Navarro JF, Mora C. Antiproteinuric effect of pentoxifylline in patients with diabetic nephropathy. Diabetes Care. 1999;22(6):1006-1008.
8. Lin SL, Chen RH, Chen YM, et al. Pentoxifylline attenuates tubulointerstitial fibrosis by blocking Smad3/4-activated transcription and profibrogenic effects of connective tissue growth factor. J Am Soc Nephrol. 2005;16(9):2702-2713.
9. Navarro JF, Milena FJ, Mora C, León C, García J. Renal pro-inflammatory cytokine gene expression in diabetic nephropathy: effect of angiotensin-converting enzyme inhibition and pentoxifylline administration. Am J Nephrol. 2006;26(6):562-570.
10. Navarro JF, Mora C, Maca M, Garca J. Inflammatory parameters are independently associated with urinary albumin in type 2 diabetes mellitus. Am J Kidney Dis. 2003;42(1):53-61.
11. Navarro JF, Mora C, Muros M, Garcia J. Urinary tumour necrosis factor-alpha excretion independently correlates with clinical markers of glomerular and tubulointerstitial injury in type 2 diabetic patients. Nephrol Dial Transplant. 2006;21(12):3428-3434.
12. Strieter RM, Remick DK, Remick DG, et al. Cellular and molecular regulation of TNF-alpha production by pentoxifylline. Biochem Biophys Res Commun. 1988;155:1230-1236.
13. Gallardo JM, Prado-Uribe MC, Amato D, Paniagua R. Inflammation and oxidative stress markers by pentoxifylline treatment in rats with chronic renal failure and high sodium intake. Arch Med Res. 2007;38(1):34-38.
14. Forrester DL, Britton J, Lewis SA, et al. Impact of adopting low sodium diet on biomarkers of inflammation and coagulation: a randomised controlled trial. J Nephrol. 2010;23(1):49-54.
15. Navarro-González JF, Jarque A, Muros M, Mora C, García J. Tumor necrosis factor-α as a therapeutic target for diabetic nephropathy. Cytokine Growth Factor Rev. 2009;20(2): 165-173.
16. Diskin CJ, Stokes TJ, Dansby LM, Radcliff L, Carter TB. Will the addition of pentoxifylline reduce proteinuria in patients with diabetic glomerulosclerosis refractory to maximal doses of both an angiotensin-converting enzyme inhibitor and an angiotensin receptor blocker? J Nephrol. 2007;20(4):410-416.
17. Lin SL, Chen YM, Chiang WC, Wu KD, Tsai TJ. Effect of pentoxifylline in addition to losartan on proteinuria and GFR in CKD: a 12-month randomized trial. Am J Kidney Dis. 2008;52 (3):464-474.
18. Perkins RM, Aboudara MC, Uy AL, Olson SW, Cushner HM, Yuan CM. Effect of pentoxifylline on GFR decline in CKD: a pilot, double-blind, randomized, placebo-controlled trial. Am J Kidney Dis. 2009;53(4):606-616.
19. Navarro JF, Mora C, Rivero A, et al. Urinary protein excretion and serum tumor necrosis factor in diabetic patients with advanced renal failure: effects of pentoxifylline administration. Am J Kidney Dis. 1999;33(3):458-463.
20. Mc Cormick BB, Sydor A, Akbari A, Fergusson D, Doucette S, Knoll G. The effect of pentoxifylline on proteinuria in diabetic kidney disease: a meta-analysis. Am J Kidney Dis. 2008;52(3): 454-463.